A forthcoming phase 1 trial evaluating the safety and efficacy of SAR439459, another anti-TGF-β monoclonal antibody, in adults with OI, is expected to yield additional insights (Table 4). The gene discussed is TGFB1; the disease is osteogenesis imperfecta.